3 research outputs found
Rana kliniÄka iskustva sa dugoroÄnom potporom (Heart Mate II)
Left ventricular assist systems (LVAS) are widely accepted nowadays as a successful tool for bridging the patients with end-stage heart failure to heart transplantation (BTT). The second generations of axial-flow devices, such as the HeartMate II, provide a safe and reliable, as well as an effective hemodynamic support in such patients, offering them an improved quality of life; they are furthermore associated with a very low rate of device malfunction or infection requiring device change. We report here of our first three patients with the implanted HM II LVAS as a BTT .UreÄaji za potporu lijevom srcu (LVAS ā left ventricular assist system) su danas prihvaÄeni kao uspijeÅ”no sredstvo za premoÅ”tenje bolesnika u zavrÅ”nom stadiju zatajivanja srca do transplantacije. Druga generacija aksijalnih pumpi, kao Å”to je HeartMate II , pruža sigurnu i uÄinkovitu hemodinamsku potporu takvim bolesnicima, poboljÅ”avajuÄi kvalitetu života. Danas su ti ureÄaji povezani sa niskom inicidencijom malfunkcije ili infekcije koje bi zahtijevale zamjenu. Prikazujemo naÅ”a tri bolesnika kojima je ugraÄen HeartMate II LVAS kao premoÅ”tenje do transplantacije
RECOVERY AFTER LONGTERM PULSATILE MECHANICAL CIRCULATORY SUPPORT IN PATIENT WITH CHRONIC HEART FAILURE: A CASE REPORT
MehaniÄka potpora cirkulaciji danas je dio standardne terapije u lijeÄenju zavrÅ”ne faze zatajivanja sistoliÄke funkcije srca. U radu opisujemo karakteristike ureÄaja Thoratec pVAD za mehaniÄku potporu cirkulaciji, tehniku ugradnje, kao i najvažnije prednosti i komplikacije primjene ureÄaja. Prikazujemo sluÄaj 41-godiÅ”njeg bolesnika s dilatacijskom kardiomiopatijom, kojemu je prvi put u Republici Hrvatskoj zbog zatajivanja srca ugraÄen ureÄaj za parakorporalnu mehaniÄku potporu lijevom srcu (LVAD), koji je nakon 130 dana potpore odstranjen zbog poboljÅ”anja srÄane funkcije.Use of mechanical circulatory support (MCS) is a part of todayās standard therapy in the treatment of end-stage heart failure. In this paper we describe characteristics of Thoratec pVAD device for MCS, implantation techniques, as well as the most important advantages and complications of application of the device. We present a 41-year-old patient with dilatated cardiomyopathy, who was the first recipient of paracorporeal left ventricular assist device (LVAD) in the Republic of Croatia due to end-stage heart failure. After heart function recovery the patient was successfully weaned from MCS after 130 days of support
Oporavak nakon dugotrajne mehaniÄke cirkulatorne potpore u bolesnika s kroniÄnim zatajivanjem srca: prikaz bolesnika [Recovery after long-term pulsatile mechanical circulatory support in patient with chronic heart failure: a case report]
Use of mechanical circulatory support (MCS) is a part of today's standard therapy in the treatment of end-stage heart failure. In this paper we describe characteristics of Thoratec pVAD device for MCS, implantation techniques, as well as the most important advantages and complications of application of the device. We present a 41-year-old patient with dilatated cardiomyopathy, who was the first recipient ofparacorporeal left ventricular assist device (LVAD) in the Republic of Croatia due to end-stage heart failure. After heart function recovery the patient was successfully weaned from MCS after 130 days of support